乐普生物:CMG901全球III期临床试验CLARITY-GASTRIC01达主要终点

南方财经网
Jul 28

乐普生物(02157.HK)发布自愿公告,公告基本信息:公司于2026年7月28日发布自愿性公告,披露其与阿斯利康合作开发的抗体偶联药物CMG901(sonesitatugvedotin,AZD0901)全球III期临床试验CLARITY-GASTRIC01取得积极顶线结果。主要内容:该试验在2L+Claudin18.2阳性晚期胃癌患者中,CMG901相较研究者选择方案显著延长总生存期(OS),...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10